Monoclonal antibodies are man-made versions of immune system proteins (antibodies) that are designed to attach to a specific target (in this case, proteins on the surface of cancer cells). These drugs can help your immune system react to and destroy the cancer cells. Some monoclonal antibodies also fight cancer in other ways.
Chemo given along with a monoclonal antibody is a standard treatment for chronic lymphocytic leukemia (CLL).
The monoclonal antibodies used to treat CLL can be divided into groups based on which protein they target.
In recent years we have seen the move away from ‘politics as usual’. Non-traditional figures have entered the political arena to disrupt the typical entrenched narratives. The election and worldwide popularity of Jacinda Ardern, New Zealand Prime Minister just one example of a new kind of leader who prioritises national wellbeing and happiness in the belief that everything else will follow.
Brigadier General (Retired) Dr. Loree Sutton Next Mayor of New York City?
Brigadier General Dr. Loree Sutton, ex-army general, physician, LGBTQ, mental healthcare advocate, is a further example of a leader who attempts to bridge the gap between people and focus on wellbeing. She is a candidate who is bringing a centrist, holistic, “quality-of-life” based approach to rejuvenating and re-inventing one of the world’s major financial, technological, and cultural capitals, New York City. https://loreeformayor.nyc@NYC Mayor’s Office.
From brigadier general to new york city mayor?
Ira Pastor ideaXme life sciences ambassador interviews General Dr. Loree Sutton a retired military officer who served as a Brigadier General in the United States Army for over 20 years (one of only 15 female generals out of the 1.3 million soldiers serving in the Army) as well as a medical psychiatrist (for a period of time the Army’s highest-ranking), who was deployed to various locations including Saudi Arabia, Iraq, Kuwait, ad Egypt in support of the first Gulf War and other missions, and is a current candidate in the 2021 New York City mayoral election.
Ira comments: Over Dr. Sutton’s career she has been awarded Legion of Merit (a military award of the United States Armed Forces that is given for exceptionally meritorious conduct in the performance of outstanding services and achievements), as well as the Bronze Star Medal, Defense Meritorious Service Medal, and Order of Military Medical Merit. Dr. Sutton is also the founding director of the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, and served as a special assistant to the Assistant Secretary of Defense for Health Affairs.
Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis (CHR) and are associated with altered neural responses to emotional stimuli in the striatum and medial temporal lobe. Using a randomised, double-blind, parallel-group design, 33 CHR patients were randomised to a single oral dose of CBD (600 mg) or placebo. Healthy controls (n = 19) were studied under identical conditions but did not receive any drug. Participants were scanned with functional magnetic resonance imaging (fMRI) during a fearful face-processing paradigm. Activation related to the CHR state and to the effects of CBD was examined using a region-of-interest approach. During fear processing, CHR participants receiving placebo (n = 15) showed greater activation than controls (n = 19) in the parahippocampal gyrus but less activation in the striatum. Within these regions, activation in the CHR group that received CBD (n = 15) was intermediate between that of the CHR placebo and control groups. These findings suggest that in CHR patients, CBD modulates brain function in regions implicated in psychosis risk and emotion processing. These findings are similar to those previously evident using a memory paradigm, suggesting that the effects of CBD on medial temporal and striatal function may be task independent.
Scientists at the University of Pittsburgh School of Medicine have isolated “the smallest biological molecule” that “completely and specifically neutralizes” the virus that causes COVID-19.
The antibody component is 10 times smaller than a full-size antibody, and has been used to create the drug Ab8, shared in the report published by the researchers in the journal Cell on Monday. The drug is seen as a potential preventative against SARS-CoV-2.
According to the report, the drug has been “highly effective in preventing and treating” SARS-CoV-2 infections in mice and hamsters during tests. The drug also reportedly does not bind to human cells, which suggests it will not have negative side effects in people.
Gold isn’t just a pretty face – it’s shown promise in fighting cancer in many studies. Now researchers have found a way to grow gold nanoparticles directly inside cancer cells within 30 minutes, which can help with imaging and even be heated up to kill the tumors.
Gold isn’t just a pretty face – it’s shown promise in fighting cancer in many studies. Now researchers have found a way to grow gold nanoparticles directly inside cancer cells within 30 minutes, which can help with imaging and even be heated up to kill the tumors.
For this new study, researchers instead found a way to grow the gold directly inside the cancer cells. The advantage is that it doesn’t require as high a concentration of gold in the cell, and it can be done much quicker than other methods.
The is a multi-sport event, an international competition in which people with physical disabilities compete against each other to complete everyday tasks using state-of-the-art technical assistance Systems (“pilots”). Besides the actual competition, the offers a platform to drive forward research on assistance systems for everyday use, and to promote dialogue with the public.
The first organised by the Swiss Federal Institute of Technology in Zurich (ETH Zurich) took place in the Swiss Arena in Kloten north of Zurich in Switzerland on 8 October 2016 and was the first international competition of this kind.[1][2][3] 66 pilots from 25 nations competed in front of a stadium with approximately 4600 spectators.
The next takes place on 13–14 November 2020 in a new format at the teams’ home base instead of in the Swiss Arena in Kloten, Zurich as it had been planned[4]. This is due to the COVID-19 pandemic which requires measures such as social distancing to be adhered. Termed the “Global Edition”, teams will set up their infrastructure for the competition at their home base and capture their races on video instead of competing physically next to each other in Zurich. officials will supervise the pilots which will start individually [5].
Pfizer Inc said on Tuesday participants were showing mild-to-moderate side effects when given either the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
(Reuters) — Pfizer Inc PFE.N said on Tuesday participants were showing mostly mild-to-moderate side effects when given either the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
The company said in a presentation to investors that side effects included fatigue, headache, chills and muscle pain. Some participants in the trial also developed fevers — including a few high fevers. The data is blinded, meaning Pfizer does not know which patients received the vaccine or a placebo.
Kathrin Jansen, Pfizer’s head of vaccine research and development, stressed that the independent data monitoring committee “has access to unblinded data so they would notify us if they have any safety concerns and have not done so to date.”
Myotonic dystrophy type I is the most common type of adult-onset muscular dystrophy. People with the condition inherit repeated DNA segments that lead to the toxic buildup of repetitive RNA, the messenger that carries a gene’s recipe to the cell’s protein-making machinery. As a result, people born with myotonic dystrophy experience progressive muscle wasting and weakness and a wide variety of other debilitating symptoms.
CRISPR-Cas9 is a technique increasingly used in efforts to correct the genetic (DNA) defects that cause a variety of diseases. A few years ago, University of California San Diego School of Medicine researchers redirected the technique to instead modify RNA in a method they call RNA-targeting Cas9 (RCas9).
In a new study, publishing September 14, 2020 in Nature Biomedical Engineering, the team demonstrates that one dose of RCas9 gene therapy can chew up toxic RNA and almost completely reverse symptoms in a mouse model of myotonic dystrophy.
